Clinical Efficacy of Rosuvastatin Combined with Edaravone in Treating Acute Cerebral Infarction in 46 Cases
Author(s): Zhang Zuonian
Pages: 27-28,29
Year: 2015 Issue: 4
Journal: China Pharmaceuticals
Keyword: rosuvastatin; edaravone; acute cerebral infarction; MMP-9; hs-CRP; IMT;
Abstract: Objective To investigate the clinical effect of rosuvastatin combined with edaravone in treating acute cerebral infarction(ACI). Methods 92 patients with ACI were divided into the study group and the control group by adopting the random number table method,46 cases in each group. The control group adopted the conventional reducing pressure,anticoagulation,prevention of brain edema, improving microcirculation and edaravone treatment,while on this basis,the study group was added with rosuvastatin. The differences in blood lipids,matrix metalloproteinase-9(MMP-9),high sensitive C reactive protein(hs-CRP),carotid artery intima-media thickness (IMT) and neural function defect scores of the American National Institutes of Health(NIHSS) after treatment were compared between the two groups. Results The hs-CRP and MMP-9 levels after treatment in the two groups were significantly decreased compared with those before treatment( P < 0. 05),but the decrease in the study group was more significant than the control group( P < 0. 05);TG,TC,HDL-C,LDL-C,IMT and NIHSS scores after treatment in the study group were significantly decreased compared with the control group( P < 0. 05); the basic cure rate in the study group was higher than that in the control group,but no efficiency was low-er than that in the control group,moreover the curative effect distribution in the study group was significantly better than that in the control group( P < 0. 05); the total effect rate in the study group was 93. 47%,which was higher than 84. 78% in the control group, but the difference was not statistically significant( P > 0. 05). Conclusion Rosuvastatin combined with edaravone can more significantly reduce the blood lipid,hs-CRP,MMP-9 levels and IMT in the patients with ACI than use edaravone alone,which conduces to im-proue the clinical efficacy.
Pages: 27-28,29
Year: 2015 Issue: 4
Journal: China Pharmaceuticals
Keyword: rosuvastatin; edaravone; acute cerebral infarction; MMP-9; hs-CRP; IMT;
Abstract: Objective To investigate the clinical effect of rosuvastatin combined with edaravone in treating acute cerebral infarction(ACI). Methods 92 patients with ACI were divided into the study group and the control group by adopting the random number table method,46 cases in each group. The control group adopted the conventional reducing pressure,anticoagulation,prevention of brain edema, improving microcirculation and edaravone treatment,while on this basis,the study group was added with rosuvastatin. The differences in blood lipids,matrix metalloproteinase-9(MMP-9),high sensitive C reactive protein(hs-CRP),carotid artery intima-media thickness (IMT) and neural function defect scores of the American National Institutes of Health(NIHSS) after treatment were compared between the two groups. Results The hs-CRP and MMP-9 levels after treatment in the two groups were significantly decreased compared with those before treatment( P < 0. 05),but the decrease in the study group was more significant than the control group( P < 0. 05);TG,TC,HDL-C,LDL-C,IMT and NIHSS scores after treatment in the study group were significantly decreased compared with the control group( P < 0. 05); the basic cure rate in the study group was higher than that in the control group,but no efficiency was low-er than that in the control group,moreover the curative effect distribution in the study group was significantly better than that in the control group( P < 0. 05); the total effect rate in the study group was 93. 47%,which was higher than 84. 78% in the control group, but the difference was not statistically significant( P > 0. 05). Conclusion Rosuvastatin combined with edaravone can more significantly reduce the blood lipid,hs-CRP,MMP-9 levels and IMT in the patients with ACI than use edaravone alone,which conduces to im-proue the clinical efficacy.
Related Articles